The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
Abstract
BACKGROUND & AIMS: Inflammatory bowel disease (IBD) is characterised by chronic intestinal inflammation, resulting from dysregulation of the mucosal immune system and compromised intestinal epithelial barrier function. The bile salt, nuclear farnesoid X receptor (FXR), was recently implicated in intestinal antibacterial defence and barrier function. The aim of this study was to investigate the therapeutic potential of FXR agonists in the treatment of intestinal inflammation in complementary in vivo and in vitro models. METHODS: Colitis was induced in wild-type (WT) and Fxr-null mice using dextran sodium sulfate, and in WT mice using trinitrobenzenesulfonic acid. Mice were treated with vehicle or the FXR agonist INT-747, and colitis symptoms were assessed daily. Epithelial permeability assays and cytokine expression analysis were conducted in mouse colon and enterocyte-like cells (Caco-2/HT29) treated with medium or INT-747. Inflammatory cytokine secretion was determined by ELISA in various human immune cell types. RESULTS: INT-747-treated WT mice are protected from DSS- and TNBS-induced colitis, as shown by significant reduction of body weight loss, epithelial permeability, rectal bleeding, colonic shortening, ulceration, inflammatory cell infiltration and goblet cell loss. Furthermore, Fxr activation in intestines of WT mice and differentiated enterocyte-like cells downregulates expression of key proinflammatory cytokines and preserves epithelial barrier function. INT-747 significantly decreases tumour necrosis factor α secretion in activated human peripheral blood mononuclear cells, purified CD14 monocytes and dendritic cells, as well as in lamina propria mononuclear cells from patients with IBD. CONCLUSIONS: FXR activation prevents chemically induced intestinal inflammation, with improvement of colitis symptoms, inhibition of epithelial permeability, and reduced goblet cell loss. Furthermore, FXR activation inhibits proinflammatory cytokine production in vivo in the mouse colonic mucosa, and ex vivo in different immune cell populations. The findings provide a rationale to explore FXR agonists as a novel therapeutic strategy for IBD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FXR agonists are known to alleviate endoplasmic reticulum stress and suppress oxidative damage by upregulating antioxidant and anti-apoptotic pathways [42, 43].”
From High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics. (2026) · cites this paper as [42]
In the citing paper
“Multiple reports regarding TGR5 function (Gadaleta et al., 2011;Hartmann et al., 2018;Inagaki et al., 2006;Vavassori et al., 2009) have indicated that a very fine balance between host-and microbiota-produced bile acids is required to support epithelial barrier function and control the inflammatory response in the intestine.”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Gadaleta et al., 2011
In the citing paper
“Activation of FXR inhibits intestinal inflammation and protects the intestinal barrier in IBD (Gadaleta et al., 2011).”
From Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway (2023) · cites this paper as Gadaleta et al., 2011
In the citing paper
“Accordingly, FXR activation by agonists GW4064 or obeticholic acid (OCA) attenuates mucosal injury, ileal barrier permeability, bacterial overgrowth and bacterial translocation in mice and rats 20,21,141,142.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [21]
In the citing paper
“treatment with a synthetic agonist of BAR has protective effects in mouse models of colitis, whereas BAR-deficient (Nr1h4−/−) mice exhibit exacerbated pathology (Gadaleta et al., 2011; Vavassori et al., 2009).”
From Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System (2017) · cites this paper as Gadaleta et al., 2011
In the citing paper
“In the small intestine, they are also very important for the maintenance of epithelial barrier function (Gadaleta et al., 2011; Inagaki et al., 2006).”
From Microbiota-related Changes in Bile Acid & Tryptophan Metabolism are Associated with Gastrointestinal Dysfunction in a Mouse Model of Autism (2017) · cites this paper as Gadaleta et al., 2011
Citations
Cites
Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,183
Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989) · Gastroenterology · doi:10.1016/s0016-5085(89)80072-1 · Cited by 2,396
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
Sartor, R. B. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0528 · Cited by 1,806
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422 · cited 1×
“Currently, phase 1 and 2 studies with INT-747 are being performed in patients with metabolic and chronic liver diseases, indicating the safe applicability of this class of compounds for the treatment of human disease.(42) Figure 8 INT-747 inhibits IFNg, IL-17 and TNFa production by lymphocyte-enriched LPMCs from IBD p…”
BackgroundPenna, G., & Adorini, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2405 · Cited by 1,257
Self-citationRegulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R. T., Shelton, J. M., Richardson, J. A., Repa, J. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509592103 · Cited by 1,164 · cited 2×
“Fxr-null mice exhibited compromised intestinal integrity at baseline, with further deterioration after bile duct ligation, which was not prevented by FXR agonist treatment.(15) Recently, FXR activation was also shown to protect against hepatic inflammation presumably by repression of NF-kB signalling in mice.”
BackgroundSelf-citationAngiogenins: a new class of microbicidal proteins involved in innate immunity
Hooper, L. V., Stappenbeck, T. S., Hong, C. V., & Gordon, J. I. (2003) · Nature Immunology · doi:10.1038/ni888 · Cited by 947
Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J., & Suchy, F. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011610200 · Cited by 804
Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function
Cario, E., Gerken, G., & Podolsky, D. K. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.056 · Cited by 697
Cited by
Sorted by citations
Items 801–875 of 875
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741360
Yin, G., Guo, Y., Ding, Q., Ma, S., Chen, F., Wang, Q., Chen, H., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26578964
Yin, G., Guo, Y., Ding, Q., Ma, S., Chen, F., Wang, Q., Chen, H., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26578967
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26143803
Huang, S., Hou, Y., Hu, M., Hu, J., & Liu, X. (2022) · Figshare · doi:10.6084/m9.figshare.21171509
Yin, G., Guo, Y., Ding, Q., Ma, S., Chen, F., Wang, Q., Chen, H., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26578961
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741375
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741366
Huang, S., Hou, Y., Hu, M., Hu, J., & Liu, X. (2022) · Figshare · doi:10.6084/m9.figshare.21171515
Yin, G., Guo, Y., Ding, Q., Ma, S., Chen, F., Wang, Q., Chen, H., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26578958
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741381
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741372
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741378
Yin, G., Guo, Y., Ding, Q., Ma, S., Chen, F., Wang, Q., Chen, H., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26578949
Huang, S., Hou, Y., Hu, M., Hu, J., & Liu, X. (2022) · Figshare · doi:10.6084/m9.figshare.21171518
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741384
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741387
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26143716
Huang, S., Hou, Y., Hu, M., Hu, J., & Liu, X. (2022) · Figshare · doi:10.6084/m9.figshare.21171512
Yin, G., Guo, Y., Ding, Q., Ma, S., Chen, F., Wang, Q., Chen, H., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26578952
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741363
Yin, G., Guo, Y., Ding, Q., Ma, S., Chen, F., Wang, Q., Chen, H., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26578955
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741369
Pi, Y., Wu, Y., Zhang, X., Lu, D., Han, D., Zhao, J., Zheng, X., Zhang, S., Ye, H., Lian, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22603987
Hu, S., Zhao, R., Yang, S., Li, Y., yin, W., Yu, S., Lyu, B., & Shen, Y. (2025) · Applied Materials Today · doi:10.1016/j.apmt.2025.103058
The role of the gut microbiota in inflammatory bowel diseases
Martinov-Nestorov, J., & Sokić-Milutinović, A. (2025) · Medicinski podmladak · doi:10.5937/mp76-62015
Bergheim, I., Cadranel, J. F. D., Chen, J., Ding, W., Eferl, R., García‐Ruiz, C., Jaeschke, H., Kazerouni, F., Lonardo, A., Mann, D. A., et al. (2026) · Exploration of Digestive Diseases · doi:10.37349/edd.2026.1005110
Yu, S.-R., Sun, R., Shi, M.-Y., Yang, M., Chen, K., Pan, Q., Zhao, L., Wu, M.-Y., & Chai, J. (2026) · Liver Research · doi:10.1016/j.livres.2026.02.001
“79,80 This divergence uncovers tissue-and disease-specific FXR agonism/antagonism to optimally balance metabolic and Abbreviations: ALD, alcoholic liver disease; ALT, alanine aminotransferase; ASH, alcoholic steatohepatitis; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; DHCA,…”
Li, C., Wu, P., Wu, Z., Chen, J., Wang, Z., Zhong, Z., Zhong, Y., & Fu, S. (2026) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2026.100180
Jin, H., Zhou, W., & Ying, R. (2026) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-026-04031-4
Chetia, D., & Borbora, S. (2026) · Journal of Datta Meghe Institute of Medical Sciences University · doi:10.4103/jdmimsu.jdmimsu_490_25
Nuclear receptors in age-related diseases: From mechanisms to drug discovery
Zhang, L., Li, X., Ren, C., Hao, Y., Deng, Y., Pan, H., Kim, Y.-B., Fan, S., Huang, C., Ge, G., et al. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103125 · Cited by 1
Pocheron, A.-L. (2019) · theses.fr (ABES) · doi:10.70675/29969b86z2649z4b67zb315za23a1106f4ef
Role of environmental factors on intestinal barrier dysfunctions reported in obesity
Postal, B. G. (2019) · theses.fr (ABES) · doi:10.70675/4b9e7a12ze552z46bez8767z3241d10852d3
Influence of bile acids metabolism on hepatic immunity in mice
Guinot, V. (2022) · theses.fr (ABES) · doi:10.70675/b69bb11eza30fz4874z9af2za6e31b2d5ad8
Analyse de la régulation de l'homéostasie des acides biliaires au sein des testicules
Holota, H. (2024) · theses.fr (ABES) · doi:10.70675/87a97831z9d93z48dazb8b7z8e7a929fc132
Mariaule, V. (2024) · theses.fr (ABES) · doi:10.70675/1d41e841zf788z4dd7z8784zc26304e24ea1
Interactions hôte-microbiote intestinal dans les maladies auto-inflammatoires monogéniques
Elhani, I. (2024) · theses.fr (ABES) · doi:10.70675/3d60157fz88efz4edazb51ezd427f44ecb7f
Fan, H., Li, W., Huang, Y., Xu, Y., Yang, W., Hu, E., Zhang, W., Yuan, H., Zhang, P., Feng, X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1790698
Fang, Y., Chi, H., Teng, J., Yang, C., Sun, Y., & Su, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1781434
Food intolerance in inflammatory bowel disease: From mechanism typing to precision management
Huang, L.-W., & Fan, Y.-H. (2026) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v34.i3.242
Shi, J., Ma, C.-Y., Zhang, X.-H., Liu, K., Liu, J.-Y., Wang, Q.-G., Wang, X.-Q., Cheng, F.-F., & Xu, T. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i17.116590
Gan, Q., Zhang, Z. F., Yue, Y., Song, W., Zhao, M., He, Y., Luo, Y., Yang, Y., Dang, S., & Zhang, Y. (2026) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2026.117544
Sun, X., Jiang, H.-L., Ma, Y.-T., Xiong, T.-Q., Leng, X.-Y., Zhao, Y.-F., Shen, X., Zhang, C., & Tang, Y.-J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08219-6
Hierarchical surface engineering of probiotics for enhanced intestinal retention and colitis therapy
郑宗珩, Liu, Y., Ju, E., Zhang, W., Zhang, Y., Wu, K., Zhang, C., Sun, K., Xu, Y., Lao, Y., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.178212
McCartney, C., Hajjar, R., & Santos, M. M. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1774501 · Cited by 1
“…et al., 2009), PXR (Shah et al., 2007), and TGF5 (Wang et al., 2011) activation has been shown to suppress NF-κ B mediated inflammation, while activation of the FXR also reduced IL-6 and TNF-α secretion and decreased intestinal permeability in a DSS-induced colitis model (Gadaleta et al., 2011).”
Wang, Y., Li, Z., & Kong, X. (2026) · Cancer Screening and Prevention · doi:10.14218/csp.2026.00033
Wang, Y., Zhou, Y., Yang, Z., Song, J., Yang, D., Zhao, H., & Tang, Q. (2026) · Journal of Food Bioactives · doi:10.26599/jfb.2026.95034447
Lopes, A. L. F., Araújo, A. K. D. S., Chaves, L. D. S., Santos, E. D. S., de Oliveira, A. C. P., da Silva, K. C., Pacheco, G., Góis, M. B., Nicolau, L. A. D., & Medeiros, J. V. R. (2026) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgag074
Cagle, R., Proll, S. C., Minot, S. S., Purcell, H. J., Zhu, W., Djukovic, D., Liu, C., Fiedler, T. L., DeMeules, M. M., Mielcarek, M. B., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1818647 · Cited by 1
Liu, Y., Wang, J., Zhang, C., Li, Z., Nie, Y., Hu, Y., Liu, C., & Tu, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08648-3
“This barrier disruption is likely multifaceted, driven by direct bile acid toxicity [50] and systemic inflammation [51].”
Altered bile acid metabolism in people with HIV correlates with systemic and intestinal inflammation
Irwin, S. L., Elliott, J. E., Li, F., Ruiz, P., Pr, A., Du, X., & Fulcher, J. A. (2026) · AIDS · doi:10.1097/qad.0000000000004585
Németh, K., Mózes, B., Bartha, T., Schilling-Tóth, B. M., Jócsák, G., Kiss, D. S., Sterczer, Á., Kis, M., & Tóth, I. (2026) · Veterinary Sciences · doi:10.3390/vetsci13080747
“Activation of intestinal FXR enforces mucosal barrier integrity—directly inducing tight junction gene transcription—reduces lipogenesis, and suppresses mucosal pro-inflammatory NF-κ B and NLRP3 inflammasome signaling, substantially mitigating inflammatory bowel disease (IBD) and colitis [16,17].”
Hu, Z., Liu, M., Zhu, C., Li, N., Chen, X., Da, B., Li, Y., & Yu, C. (2026) · Inflammation Research · doi:10.1007/s00011-026-02332-4
Li, X., Jing, B. Q., 夏春森, Duan, J., Zhang, T., Li, H., & Che, H. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c16899
Yuan, W., Wen, M., Chen, M., Zhou, Y., Zhu, M., Zhang, Y., Cao, Y., Zou, Y., Li, Z., Wang, Z., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10415660/v1
Mu, K., He, M., Liao, R., Shao, C., Xie, P., Xie, J., Liu, Y., Ju, Z., Zhong, K., Yuan, Y., et al. (2026) · Nutrients · doi:10.3390/nu18162641
Seethaler, B., Basrai, M., Delzenne, N. M., Walter, J., Nguyen, N. K., & Bischoff, S. C. (2026) · Microbiome · doi:10.1186/s40168-026-02501-x
“Because bile acids affect epithelial barrier integrity [44] and mucosal immune responses via receptors such as FXR and TGR5 [45, 46], this pathway may represent an additional mechanism linking Lachnospiraceae to gut barrier function.”
Chen, Y., Xiao, J., Xiao, L., Chen, A., He, L., & Wang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1889686
SMRT regulation of nuclear receptors orchestrates bile acid homeostasis
Kim, K., Fang, S., Hong, S.-H., Cho, H., Leblanc, M., Jacinto, S., Schnabl, B., Atkins, A. R., Yu, R. T., Liddle, C., et al. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01823-y
Xiao, X., Gong, Q., Zheng, X.-J., Zhou, J.-H., Shao, C., Zuo, Q., & Cai, C.-H. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1867553
Senna, M. M., Shiha, N. A., Zaki, H. F., Ramadan, L. A. A., & Mustafa, A. M. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02389-x
“However, it garnered significant attention for its broader therapeutic potential in the management of autoimmune and inflammatory diseases (Gadaleta et al. 2011a ; Ho and Steinman 2016 ; Fei et al. 2019).”
Jiang, X., Zhang, J., & Li, K. (2026) · Molecular Biology · doi:10.1134/s0026893326600443
Maz, M. P., Zhang, L., Ma, F., Gharaee‐Kermani, M., Klein, B., Moallemian, R., Nguyen, N. T. K., Cai, Y., Loftus, S. N., Billi, A. C., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adw1914
Sun, L., Chen, H., Fan, W. J., Shi, Z. Y., Zhao, Y., Wang, Y., & Nie, Y. (2026) · Journal of Digestive Diseases · doi:10.1111/1751-2980.70072
Pleiotropic roles of microbial bile acid metabolism in intestinal health and diseases
Qi, M., Liu, X., & Gonzalez, F. J. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.09.010
Yang, R., Zhang, S., Fu, Z., Yang, Y., Wang, Q., Zhou, Y., Li, J., Yang, R., Ning, S., Shi, Y., et al. (2026) · Medicinal Research Reviews · doi:10.1002/med.70117
Gut Microbiota-Induced Metabolic Reprogramming of the Host Immune System
Roy, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-30306-6_7
BindingDB Entry 50018517: Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.
BindingDB (2024) · UC San Diego · doi:10.7270/q2ff3xjm
Metadata
- Authors
- Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., Penna, G., Laverny, G., Adorini, L., Moschetta, A., & Mil, S. W. C. V.
- Affiliations
- University Medical Center Utrecht (NL)
- Mario Negri Sud Foundation (IT)
- Corresponding author
- Mil, Saskia W C van
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2011-01-17
- Volume
- 60
- Issue
- 4
- Pages
- 463-472
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2134059673
- Cited by
- 870
- References
- 43
- Citations by year
- 2026: 72 · 2025: 87 · 2024: 95 · 2023: 75 · 2022: 96 · 2021: 84 · 2020: 59 · 2019: 46 · 2018: 35 · 2017: 44 · 2016: 40 · 2015: 36 · 2014: 29 · 2013: 35 · 2012: 21
- FWCI
- 19.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Intercept Pharmaceuticals
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- farnesoid X receptor, FXR agonists, inflammatory bowel disease, colitis, intestinal barrier function, epithelial permeability, goblet cell loss, inflammatory cytokines, TNF-α, dendritic cells, monocytes, lamina propria, bile salts, DSS-induced colitis
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Chenodeoxycholic Acid, Colon, Disease Models, Animal, Drug Evaluation, Preclinical, Gene Expression Regulation, Humans, Ileum, Intestinal Absorption, Mice, Inbred C57BL, Trinitrobenzenesulfonic Acid, Tumor Necrosis Factor-alpha, Inflammatory Bowel Diseases, Cytokines, Dextran Sulfate, Receptors, Cytoplasmic and Nuclear, Inflammation Mediators, Caco-2 Cells, Reverse Transcriptase Polymerase Chain Reaction, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
